Skip to content

Erasca, Inc. ERAS Stock-Based Comp

Stock-Based Comp at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$146M+1.4%
Eli Lilly logo
Eli LillyLLY
$161M+4.5%
Pfizer logo
PfizerPFE
$272M+60.0%
Amgen logo
AmgenAMGN
$75M-11.8%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$87.3M+248%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$10.8M+48.8%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s stock-based comp?
Erasca, Inc. (ERAS) reported stock-based comp of $8.46M in Q1 2026.
How has Erasca, Inc.'s stock-based comp changed year-over-year?
Erasca, Inc.'s stock-based comp increased by 26.0% year-over-year, from $6.71M to $8.46M.
What is the long-term trend for Erasca, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), Erasca, Inc.'s stock-based comp has grown at a 31.5% compound annual growth rate (CAGR), from $8.33M to $24.9M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.